Business
Braxia Scientific Reports Q3 2023 Financial Results and Provides Update on Acquisition Under LOI with Irwin Naturals
Braxia Health ketamine treatments up 29% YoY in Q3 2023 and revenue up 50.5% YoY Toronto, Onta...
About this update from Braxia Scientific Corp
[{"type":"text","content":"Braxia Scientific Reports Q3 2023 Financial Results and Provides Update on Acquisition Under LOI with Irwin NaturalsBraxia Health ketamine treatments up 29% YoY in Q3 2023 and revenue up 50.5% YoYToronto, Ontario--(Newsfile Corp. - March 1, 2023) - Braxia Scientific Corp. (CSE: BRAX) (OTC Pink: BRAXF) (FSE: 4960), (\"Braxia Scientific\", or the \"Company\"), a medical research and telemedicine company with clinics providing innovative ketamine and psilocybin treatments for depression and related disorders, today announced the filing of its financial statements and management discussion and analysis for the third quarter ended December 31, 2023. The Company also provided an update on the proposed acquisition of the Company by Irwin Naturals Inc. (CSE: IWIN) (OTCQB: IWINF) (FSE: 97X) (\"Irwin\") as outlined in the non-binding Letter of Intent (\"LOI\") announced January 27, 2023. Complete financial statements along with related management discussion and analysis and the LOI can be found in the System for Electronic Document Analysis and Retrieval (SEDAR), the electronic filing system for the disclosure documents of issuers across Canada, at www.SEDAR.com. \"We continued to make progress on our priorities to scale our clinics, technology and people in order to address increasing demand for treatments. At the same time, we have completed and funded our psilocybin clinical trial and are preparing to publish our results,\" said Dr. Roger McIntyre, CEO Braxia Scientific. \"Looking ahead, we are focused on accelerating our strategic initiatives with Irwin to create the market leader in North American mental health treatment. Together, we are aiming to build a large network of clinics, enhanced by our KetaMD telehealth platform, that will provide access to innovative treatments while also serving pharmaceutical sponsors by carrying out in-human clinical trials to assist in the development of novel therapeutics for potential future marketing authorization from FDA and other health regulators globally.\"Corporate Update and Recent HighlightsThe Company previously announced it had entered into an LOI to be acquired by Irwin. The Company's management team has continued to work diligently with Irwin towards completing a definitive and binding arrangement agreement (the \"Arrangement Agreement\") for the transaction and anticipates executing t...